Aeglea Bio Therapeutics Inc (AGLE) Given $18.50 Consensus Target Price by Brokerages

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has earned a consensus broker rating score of 0.00 () from the three brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.

Brokerages have set a one year consensus price target of $18.50 for the company, according to Zacks. Zacks has also given Aeglea Bio Therapeutics an industry rank of 148 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 10th.

In other news, major shareholder Orbimed Advisors Llc purchased 109,300 shares of Aeglea Bio Therapeutics stock in a transaction that occurred on Tuesday, February 21st. The shares were acquired at an average price of $5.16 per share, for a total transaction of $563,988.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Several hedge funds have recently bought and sold shares of the company. Norges Bank purchased a new stake in Aeglea Bio Therapeutics during the fourth quarter valued at about $275,000. Perceptive Advisors LLC purchased a new stake in Aeglea Bio Therapeutics during the fourth quarter valued at about $451,000. Alyeska Investment Group L.P. raised its stake in Aeglea Bio Therapeutics by 9.2% in the fourth quarter. Alyeska Investment Group L.P. now owns 119,707 shares of the company’s stock valued at $521,000 after buying an additional 10,062 shares in the last quarter. Sio Capital Management LLC raised its stake in Aeglea Bio Therapeutics by 8.8% in the third quarter. Sio Capital Management LLC now owns 154,332 shares of the company’s stock valued at $989,000 after buying an additional 12,458 shares in the last quarter. Finally, Baker BROS. Advisors LP purchased a new stake in Aeglea Bio Therapeutics during the third quarter valued at about $2,591,000. Institutional investors and hedge funds own 43.85% of the company’s stock.

Your IP Address:

Shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) opened at 8.03 on Tuesday. The firm’s market cap is $107.84 million. Aeglea Bio Therapeutics has a 12-month low of $3.66 and a 12-month high of $12.75. The firm’s 50-day moving average is $5.51 and its 200-day moving average is $5.80.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

5 Day Chart for NASDAQ:AGLE

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply